Liminatus Pharma (LIMN) Operating Income (2024 - 2026)
Liminatus Pharma (LIMN) posted Operating Income of -$1.1 million for Q1 2026, down 24.51% sequentially from -$884211.0 in Q4 2025, and down 316.66% YoY from $508123.3 in Q1 2025.
Liminatus Pharma (LIMN) Operating Income (2024 - 2026) Analysis & Trends
Liminatus Pharma has reported Operating Income for 3 years, with the latest figure at -$1.1 million in Q1 2026.
- Quarterly Operating Income fell 316.66% year-over-year to -$1.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$3.8 million (down 101.97% YoY) and the FY2025 annual result came in at -$3.0 million, up 10.88% from the prior year.
- Operating Income slipped to -$1.1 million in Q1 2026 per LIMN's latest filing, from -$884211.0 in the prior quarter.
- Over five years, Operating Income peaked at -$167077.0 in Q4 2024 and troughed at -$1.1 million in Q2 2025.
- A 3-year average of -$711019.0 and a median of -$792690.5 in 2025 frame the typical range for Operating Income.
- The widest YoY moves for Operating Income: up 22.99% in 2025, down 429.22% in 2025.
- Over 3 years, Operating Income stood at -$167077.0 in 2024, then slumped by 429.22% to -$884211.0 in 2025, then retreated by 24.51% to -$1.1 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$1.1 million, -$884211.0, and -$701170.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.89 Bn | 131.04 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.05 Bn | 78.06 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 65.56 Bn | 60.38 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 55.46 Bn | 50.32 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 27.70 Bn | 9.30 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.38 Bn | 26.54 Bn | - | 133.12 Mn |
| 10 | Liminatus Pharma | 265.71 Mn | 265.71 Mn | - | -1.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.10 Mn |
| Dec 31, 2025 | -884,211.00 |
| Sep 30, 2025 | -701,170.00 |
| Jun 30, 2025 | -1.12 Mn |
| Mar 31, 2025 | -264,220.00 |
| Dec 31, 2024 | -167,077.00 |
| Sep 30, 2024 | -543,147.00 |
| Jun 30, 2024 | -909,218.00 |